WTX212
/ Westlake Therap
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
December 09, 2025
Reboot-107: A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Sun Yat-sen University
Monotherapy • New P1 trial • Oncology • Solid Tumor
April 23, 2025
Effect of erythrocyte-antibody conjugates on cancers resistant to checkpoint blockade immunotherapy: A phase I trial.
(ASCO 2025)
- P1 | "Our study suggests that PD-1 blockade in the spleen using erythrocyte-antibody conjugates triggers systemic anti-tumor responses while maintaining a favorable safety profile. Erythrocyte-drug conjugates represent a novel approach for targeting immune cells in the spleen, with broad implications for cancer treatment and drug development."
Checkpoint block • Checkpoint inhibition • P1 data • Oncology • Solid Tumor
January 16, 2025
A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=44 | Recruiting | Sponsor: Zhejiang University | Trial completion date: May 2025 ➔ Aug 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026
IO biomarker • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • PD-L1
October 04, 2024
Erythrocyte-αPD-1 conjugates suppress cancers with resistance to checkpoint blockade immunotherapy
(SITC 2024)
- P1 | "Additionally, αPD-1-Ery treatment rapidly reduced the number of immunosuppressive myeloid cells and stimulated T cell responses in the peripheral blood of all patients, consistent with preclinical findings. Conclusions These findings suggested that erythrocyte-antibody conjugates effectively target the spleen and reprogram the TME to overcome immunotherapy resistance."
Checkpoint block • Checkpoint inhibition • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS
October 04, 2024
Erythrocyte-αPD-1 conjugates suppress cancers with resistance to checkpoint blockade immunotherapy
(SITC 2024)
- P1 | "Additionally, αPD-1-Ery treatment rapidly reduced the number of immunosuppressive myeloid cells and stimulated T cell responses in the peripheral blood of all patients, consistent with preclinical findings. Conclusions These findings suggested that erythrocyte-antibody conjugates effectively target the spleen and reprogram the TME to overcome immunotherapy resistance."
Checkpoint block • Checkpoint inhibition • Breast Cancer • Lung Cancer • Oncology • Solid Tumor • KRAS
July 30, 2024
Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=39 | Not yet recruiting | Sponsor: Zhejiang Provincial People's Hospital
Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • Solid Tumor
July 24, 2024
FIH: Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Westlake Therapeutics | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025
Metastases • Trial completion date • Trial primary completion date • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor
April 25, 2024
Erythrocyte-αPD-1 conjugates overcome resistance to checkpoint blockade immunotherapy: A first-in-human study.
(ASCO 2024)
- P1 | "WTX-212 treatment is safe and tolerable and shows promising clinical signs in cancer patients resistant to anti-PD-1 immunotherapy, supporting further investigation and exploration of WTX-212 monotherapy and combination therapy."
Checkpoint block • Checkpoint inhibition • P1 data • Cervical Cancer • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD8
May 14, 2024
A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=44 | Recruiting | Sponsor: Zhejiang University | Not yet recruiting ➔ Recruiting
Enrollment open • IO biomarker • Metastases • Oncology • Solid Tumor • PD-L1
March 06, 2024
An Erythrocyte-αPD-1 conjugate suppresses cancers resistant to checkpoint blockade immunotherapy: A first-in-human study
(AACR 2024)
- P1 | "The initial promising data support further investigation and exploration of the combination therapy strategies to expand the therapeutic potential of WTX-212 in cancer patients. Erythrocyte-drug conjugation may serve as a unique strategy for targeting the peripheral immune system to treat cancers."
Checkpoint block • Checkpoint inhibition • P1 data • Cervical Cancer • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
March 26, 2024
Reboot-105: WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
(clinicaltrials.gov)
- P1 | N=20 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • PD-1 • PD-L1
October 30, 2023
A Exploratory Trial of WTX212A Injection in the Treatment of Patients With Advanced Lung Cancer
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Metastases • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
August 01, 2023
Reboot-101: Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Westlake Therapeutics | Trial completion date: Dec 2023 ➔ Jul 2024
Metastases • Trial completion date • Hematological Disorders • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor
April 27, 2023
WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy.
(ASCO 2023)
- P1 | "WTX212 demonstrated anti-tumor activities by activating the peripheral immune system to overcome resistance to immunotherapy in both preclinical models and human patients. WTX212 is well-tolerated supporting the future clinical trials."
Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Lung Cancer • Oncology • Solid Tumor • CD8 • PD-L1
1 to 14
Of
14
Go to page
1